As higher rates of cancer cell migration and invasion are a hallmark of aggressive cancers, our data suggest that PDK1 is a suitable target for therapeutic intervention in prostate cancer and support the clinical development of PDK1 inhibitors for prostate cancer. The gene discussed is PDK1; the disease is cancer.